Omnicell Inc
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for th… Read more
Omnicell Inc (OMCL) - Net Assets
Latest net assets as of December 2025: $1.23 Billion USD
Based on the latest financial reports, Omnicell Inc (OMCL) has net assets worth $1.23 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.97 Billion) and total liabilities ($742.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.23 Billion |
| % of Total Assets | 62.38% |
| Annual Growth Rate | N/A |
| 5-Year Change | 7.42% |
| 10-Year Change | 185.4% |
| Growth Volatility | 42.39 |
Omnicell Inc - Net Assets Trend (2000–2025)
This chart illustrates how Omnicell Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Omnicell Inc (2000–2025)
The table below shows the annual net assets of Omnicell Inc from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.23 Billion | -0.92% |
| 2024-12-31 | $1.24 Billion | +4.57% |
| 2023-12-31 | $1.19 Billion | +5.20% |
| 2022-12-31 | $1.13 Billion | -1.44% |
| 2021-12-31 | $1.15 Billion | +18.52% |
| 2020-12-31 | $967.50 Million | +14.46% |
| 2019-12-31 | $845.25 Million | +24.37% |
| 2018-12-31 | $679.62 Million | +31.40% |
| 2017-12-31 | $517.20 Million | +19.83% |
| 2016-12-31 | $431.61 Million | +7.26% |
| 2015-12-31 | $402.39 Million | +3.15% |
| 2014-12-31 | $390.10 Million | +11.99% |
| 2013-12-31 | $348.33 Million | +13.25% |
| 2012-12-31 | $307.58 Million | +8.72% |
| 2011-12-31 | $282.91 Million | +6.56% |
| 2010-12-31 | $265.49 Million | +9.57% |
| 2009-12-31 | $242.30 Million | +3.75% |
| 2008-12-31 | $233.56 Million | -8.28% |
| 2007-12-31 | $254.64 Million | +182.94% |
| 2006-12-31 | $90.00 Million | +62.92% |
| 2005-12-31 | $55.24 Million | +2.87% |
| 2004-12-31 | $53.70 Million | +54.49% |
| 2003-12-31 | $34.76 Million | +113.16% |
| 2002-12-31 | $16.31 Million | -16.81% |
| 2001-12-31 | $19.60 Million | +178.33% |
| 2000-12-31 | $-25.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Omnicell Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 47773500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $384.94 Million | 31.25% |
| Common Stock | $58.00K | 0.00% |
| Other Comprehensive Income | $-8.85 Million | -0.72% |
| Other Components | $855.67 Million | 69.46% |
| Total Equity | $1.23 Billion | 100.00% |
Omnicell Inc Competitors by Market Cap
The table below lists competitors of Omnicell Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Allos S.A.
SA:ALOS3
|
$1.56 Billion |
|
BIGBEAR.AI HOLD. DL-0001
F:28K1
|
$1.56 Billion |
|
Robotis Co.Ltd
KQ:108490
|
$1.56 Billion |
|
Internet Initiative Japan Inc
F:I6I
|
$1.56 Billion |
|
Jiaozuo Wanfang Aluminum
SHE:000612
|
$1.56 Billion |
|
Shift4 Payments Inc
NYSE:FOUR
|
$1.56 Billion |
|
Dynavax Technologies Corporation
NASDAQ:DVAX
|
$1.56 Billion |
|
Tongyu Heavy Industry
SHE:300185
|
$1.55 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Omnicell Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,243,313,000 to 1,231,814,000, a change of -11,499,000 (-0.9%).
- Net income of 2,052,000 contributed positively to equity growth.
- Share repurchases of 77,600,000 reduced equity.
- Other comprehensive income increased equity by 8,341,000.
- Other factors increased equity by 55,708,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $2.05 Million | +0.17% |
| Share Repurchases | $77.60 Million | -6.3% |
| Other Comprehensive Income | $8.34 Million | +0.68% |
| Other Changes | $55.71 Million | +4.52% |
| Total Change | $- | -0.92% |
Book Value vs Market Value Analysis
This analysis compares Omnicell Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.32x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $-14.69 | $35.09 | x |
| 2001-12-31 | $1.90 | $35.09 | x |
| 2002-12-31 | $0.75 | $35.09 | x |
| 2003-12-31 | $1.37 | $35.09 | x |
| 2004-12-31 | $1.94 | $35.09 | x |
| 2005-12-31 | $2.13 | $35.09 | x |
| 2006-12-31 | $3.11 | $35.09 | x |
| 2007-12-31 | $7.53 | $35.09 | x |
| 2008-12-31 | $7.05 | $35.09 | x |
| 2009-12-31 | $7.56 | $35.09 | x |
| 2010-12-31 | $7.92 | $35.09 | x |
| 2011-12-31 | $8.30 | $35.09 | x |
| 2012-12-31 | $8.99 | $35.09 | x |
| 2013-12-31 | $9.74 | $35.09 | x |
| 2014-12-31 | $10.65 | $35.09 | x |
| 2015-12-31 | $10.96 | $35.09 | x |
| 2016-12-31 | $11.71 | $35.09 | x |
| 2017-12-31 | $13.36 | $35.09 | x |
| 2018-12-31 | $16.76 | $35.09 | x |
| 2019-12-31 | $19.68 | $35.09 | x |
| 2020-12-31 | $22.12 | $35.09 | x |
| 2021-12-31 | $23.92 | $35.09 | x |
| 2022-12-31 | $24.63 | $35.09 | x |
| 2023-12-31 | $26.30 | $35.09 | x |
| 2024-12-31 | $26.88 | $35.09 | x |
| 2025-12-31 | $26.57 | $35.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Omnicell Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.17%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 1.60x
- Recent ROE (0.17%) is below the historical average (3.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | -30.86% | 1.53x | 0.00x | $-18.29 Million |
| 2001 | -5.95% | -1.34% | 1.21x | 3.68x | $-3.13 Million |
| 2002 | -30.90% | -5.75% | 1.34x | 4.02x | $-6.67 Million |
| 2003 | 21.02% | 7.15% | 1.21x | 2.43x | $3.83 Million |
| 2004 | 19.74% | 8.55% | 1.25x | 1.85x | $5.23 Million |
| 2005 | -3.75% | -1.71% | 1.21x | 1.82x | $-7.60 Million |
| 2006 | 11.52% | 6.70% | 1.00x | 1.72x | $1.37 Million |
| 2007 | 17.00% | 20.32% | 0.65x | 1.29x | $17.83 Million |
| 2008 | 5.45% | 5.05% | 0.81x | 1.32x | $-10.63 Million |
| 2009 | 0.18% | 0.21% | 0.66x | 1.33x | $-23.79 Million |
| 2010 | 1.84% | 2.20% | 0.65x | 1.29x | $-21.66 Million |
| 2011 | 3.67% | 4.23% | 0.68x | 1.28x | $-17.90 Million |
| 2012 | 5.25% | 5.15% | 0.71x | 1.44x | $-14.60 Million |
| 2013 | 6.88% | 6.30% | 0.77x | 1.41x | $-10.85 Million |
| 2014 | 7.82% | 6.92% | 0.79x | 1.44x | $-8.49 Million |
| 2015 | 7.64% | 6.35% | 0.84x | 1.44x | $-9.48 Million |
| 2016 | 0.14% | 0.09% | 0.74x | 2.17x | $-42.56 Million |
| 2017 | 3.98% | 2.88% | 0.73x | 1.90x | $-31.11 Million |
| 2018 | 5.55% | 4.79% | 0.73x | 1.59x | $-30.23 Million |
| 2019 | 7.26% | 6.84% | 0.72x | 1.47x | $-23.19 Million |
| 2020 | 3.33% | 3.61% | 0.49x | 1.89x | $-64.56 Million |
| 2021 | 6.79% | 6.88% | 0.53x | 1.87x | $-36.82 Million |
| 2022 | 0.50% | 0.44% | 0.59x | 1.96x | $-107.37 Million |
| 2023 | -1.71% | -1.78% | 0.52x | 1.87x | $-139.27 Million |
| 2024 | 1.01% | 1.13% | 0.52x | 1.71x | $-111.80 Million |
| 2025 | 0.17% | 0.17% | 0.60x | 1.60x | $-121.13 Million |
Industry Comparison
This section compares Omnicell Inc's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $79,108,599
- Average return on equity (ROE) among peers: -247.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Omnicell Inc (OMCL) | $1.23 Billion | 0.00% | 0.60x | $1.56 Billion |
| Accolade, Inc. (ACCD) | $473.79 Million | -97.02% | 0.91x | $448.32 Million |
| Achiko AG (ACHKF) | $-4.58 Million | 0.00% | 0.00x | $314.42K |
| Ascom Holding AG (ACMLF) | $78.70 Million | 22.11% | 1.51x | $152.13 Million |
| Accelera Innovations Inc (ACNV) | $-462.52K | 0.00% | 0.00x | $5.72K |
| Aclarion Inc (ACON) | $-7.08 Million | 0.00% | 0.00x | $1.89 Million |
| Alternate Health Corp (AHGIF) | $1.07 Million | -2231.82% | 7.94x | $6.50K |
| AI/ML Innovations Inc (AIMLF) | $2.09 Million | -130.52% | 0.72x | $6.84 Million |
| NetraMark Holdings Inc. (AINMF) | $-198.56K | 0.00% | 0.00x | $70.13 Million |
| AMJ Global Technology (AMJT) | $-21.78K | 0.00% | 0.00x | $10.99 Million |
| American Well Corp (AMWL) | $247.79 Million | -38.62% | 0.31x | $78.62 Million |